閩信(00222.HK)認購集友銀行資本證券 涉資300萬美元
閩信集團(00222.HK)公布,公司昨日(19日)認購集友銀行將發行的資本證券,年利率8厘,資本證券為沒有固定贖回日期的永續證券,認購金額為300萬美元(約2,355萬港元)。
公司指出,於8月15日至9月15日期間,集團透過福建閩信於集友銀行存放稱為結構性存款的若干存款,預期回報率2.8至2.9厘,於相關時間的最高風險金額為8,500萬元人民幣(約9,368萬港元)。
閩信目前持有廈銀約8.85%股權,同時廈銀被分類為閩信的聯營公司。公司控股股東福建投資集團目前實益持有廈銀約13.13%股權。廈銀目前持有集友銀行約69.63%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.